Amarillo Biosciences licensee in Taiwan and China is CytoPharm, Inc., a Taipei, Taiwan-based biopharmaceutical company whose parent company is Vita Genomics, Inc., the largest biotech company in Taiwan specializing in pharmacogenomics and specialty Clinical Research Organization. Both CytoPharm and Vita Genomics are affiliates of Ho Tung Chemical Corp. Ltd., one of the largest petrochemical companies in Taiwan, and a publicly traded company whose 2005 revenues exceeded NTD 35 billion.
Under the terms of the Agreement, between CytoPharm and ABI, CytoPharm and its subsidiary will conduct and fund all clinical trials, and seek regulatory approvals in both China and Taiwan (the Territory) to launch low dose oral interferon for influenza, hepatitis B, and hepatitis C indications. CytoPharm has entered into discussions with regulatory agencies in the Territory to conduct their first clinical trial in 152 hepatitis C patients. The trial is expected to commence in late 2007 or early 2008.
read more
Subscribe to:
Post Comments (Atom)
1 comment:
I was diagnosed as HEPATITIS B carrier in 2013 with fibrosis of the
liver already present. I started on antiviral medications which
reduced the viral load initially. After a couple of years the virus
became resistant. I started on HEPATITIS B Herbal treatment from
ULTIMATE LIFE CLINIC (www.ultimatelifeclinic.com) in March, 2020. Their
treatment totally reversed the virus. I did another blood test after
the 6 months long treatment and tested negative to the virus. Amazing
Post a Comment